Endoleak (30‐day) · people diagnosed with RAAA
1 finding from 1 review
Myocardial infarction (0 to 30 days) · people diagnosed with RAAA
Emergency endovascular aneurysm repair showed no clear difference in complication: myocardial infarction (30‐day) compared with conventional open repair (low certainty).
1 finding from 1 review
Complication: renal complications (moderate or severe) (30‐day) · people diagnosed with RAAA
Emergency endovascular aneurysm repair showed no clear difference in complication: renal complications (moderate or severe) (30‐day) compared with conventional open repair (low certainty).
1 finding from 1 review
Complication: respiratory failure (30‐day) · people diagnosed with RAAA
Emergency endovascular aneurysm repair showed no clear difference in complication: respiratory failure (30‐day) compared with conventional open repair (low certainty).
1 finding from 1 review
Complication: bowel ischaemia (30‐day) · people diagnosed with RAAA
Emergency endovascular aneurysm repair may leads to lower complication: bowel ischaemia (30‐day) compared with conventional open repair (low certainty).
1 finding from 1 review
All‐cause mortality (7 days ‐ 3 months) · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in all‐cause mortality (7 days ‐ 3 months) compared with low molecular weight heparin (low certainty).
1 finding from 1 review
Major bleedingd (3 months) · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in major bleedingd (7 days ‐ 12 months) compared with intravenous unfractionated heparin (low certainty).
1 finding from 1 review
All‐cause mortality (5 days to 12 months) · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in all‐cause mortality (5 days to 12 months) compared with intravenous unfractionated heparin (low certainty).
1 finding from 1 review
All‐cause mortality, 30 days1 · patients of any age with AAA less than 30 mm in diameter
Metoprolol showed no clear difference in all‐cause mortality, 30 days1 compared with placebo (low certainty).
1 finding from 1 review
All cardiovascular death · patients of any age with AAA less than 30 mm in diameter
Metoprolol showed no clear difference in cardiovascular death, 30 days3 compared with placebo (low certainty).
1 finding from 1 review
AAA‐related death, 30 days4 · patients of any age with AAA less than 30 mm in diameter
Metoprolol showed no clear difference in AAA‐related death, 30 days4 compared with placebo (low certainty).
1 finding from 1 review
Nonfatal cardiovascular event, 30 days5 · patients of any age with AAA less than 30 mm in diameter
Metoprolol showed no clear difference in nonfatal cardiovascular event, 30 days5 compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality/survival (> 30 days) · People undergoing elective abdominal aortic aneurysm repair
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Duration of ICU stay · People undergoing elective abdominal aortic aneurysm repair
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Length of hospital stay · People undergoing elective abdominal aortic aneurysm repair
1 finding from 1 review
Symptomatic VTE · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Heparin showed no clear difference in symptomatic VTE (DVT and PE) Treatment duration 28 ‐ 42 days compared with placebo (high certainty).
1 finding from 1 review
Major bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Vitamin K antagonists showed no clear difference in bleeding ‐ major Treatment duration 28 ‐ 42 days compared with placebo (low certainty).
1 finding from 1 review
Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Minor bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptomatic VTE · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
DOAC probably leads to lower symptomatic VTE (DVT and PE) Treatment duration 28 ‐ 42 days compared with placebo (moderate certainty).
1 finding from 1 review